Results 91 to 100 of about 49,657 (223)

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis [PDF]

, 2015
Short communication[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods.
Bañón, S, Casado, José Luis, Castro-Iglesias, Ángeles, Mena, Álvaro, Moreno, A, Moreno, S, Pedreira, José D., Quereda, C   +7 more
core   +2 more sources

Molecular Epidemiological Surveillance of HIV-1 Genotypes and Drug Resistance Profiles in Wuhan, Central China

Viruses
The global distribution of HIV-1 subtypes exhibits significant regional variations, with evolving epidemiological patterns over time. China currently experiences concurrent circulation of multiple HIV-1 subtypes, and the transmission landscape is ...
Qiqi Zhang, Mingzhe Yan, Jingxin Huang, Yujie Liu, Hanji Wang, Sheng Feng, Zheng Dong, Dilihumaer Abulimiti, Youping Wang, Ke Liang, Yong Feng   +10 more
doaj   +1 more source

Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. [PDF]

, 1987
Primary human monocyte-derived macrophages (MDM) were shown to have diminished deoxynucleoside kinase activities compared to T lymphoblasts, and a reduced ability to phosphorylate dideoxynucleosides with anti-human immunodeficiency virus (HIV) activity ...
Carson, DA, Kornbluth, RS, Richman, DD
core  

Mutational Patterns Associated with the 69 Insertion Complex in Multi-drug-resistant HIV-1 Reverse Transcriptase that Confer Increased Excision Activity and High-level Resistance to Zidovudine [PDF]

, 2001
Human immunodeficiency virus type 1 (HIV-1) strains having dipeptide insertions in the fingers subdomain and other drug resistance-related mutations scattered throughout their reverse transcriptase (RT)-coding region show high-level resistance to ...
Cases-González, Clara E., Franco, Sandra, Martínez, Miguel Ángel, Menéndez-Arias, Luis   +3 more
core   +1 more source

EVOLUTION OF PATIENTS WITH AIDS AFTER cART: CLINICAL AND LABORATORY EVOLUTION OF PATIENTS WITH AIDS AFTER 48 WEEKS OF ANTIRETROVIRAL TREATMENT

Revista do Instituto de Medicina Tropical de São Paulo, 2013
SUMMARY Combination Antiretroviral Therapy (cART) aims to inhibit viral replication, delay immunodeficiency progression and improve survival in AIDS patients.
Ana Esther Carvalho Gomes Fukumoto, Cristiano Claudino Oliveira, Karen Ingrid Tasca, Lenice do Rosario de Souza   +3 more
doaj   +1 more source

Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. [PDF]

, 2007
OBJECTIVE: Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited. We aimed to describe the clinical,
Akao, K, Ford, N, Gupta, J, Janssens, B, Nerrienet, E, Nouhin, J, Raleigh, B, Soeung, S, Te, V, Vun, M   +9 more
core   +2 more sources

CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. [PDF]

, 2012
BACKGROUND: Most adults infected with HIV achieve viral suppression within a year of starting combination antiretroviral therapy (cART). It is important to understand the risk of AIDS events or death for patients with a suppressed viral load.
A. Antinori, A. Antoniadou, A. Castagna, A. Castagna, A. Cozzi-Lepri, A. D’, A. Mocroft, A. Mocroft, A. Mocroft, A. Noguera-Julian, A. Phillips, A. Rauch, A. Scherrer, B. Gazzard, B. Ledergerber, C. Colin, C. Leport, C. Lewden, C. Mussini, C. Mussini, C. Sabin, C. Sabin, C. Smit, C. Stephan, C. Stephan, C. Thorne, C. Thorne, C. Torti, C. Torti, C. Torti, D. Costagliola, D. Gibb, D. Haerry, E. Girardi, F. Dabis, F. de Wolf, F. Engsig, F. Gutierrez, F. Raffi, G. Chene, G. Fatkenheuer, G. Touloumi, H. Bucher, H. Bucher, H. Bucher, H. Furrer, H. Furrer, H. Furrer, I. Weller, J. Bohlius, J. Casabona, J. Casabona, J. Del Amo, J. Ghosn, J. Ghosn, J. Grarup, J. Kjaer, J. Miro, J. Munoz, J. Ramos, J. Reekie, J. Sterne, J. Warszawski, J.M. Miro, L. Galli, L. Meyer, L. Meyer, L. Meyer, L. Wittkop, M. Battegay, M. Battegay, M. Dorrucci, M. Egger, M. Fisher, M. Garrido, M. Paulsen, M. Prins, M. Prins, M. Psichogiou, M. Puoti, M. Sharland, M. Sharland, M.M. Krause, N. Brockmeyer, N. Obel, N. Obel, N. Obel, O. Kirk, O. Kirk, O. Kirk, O. Kirk, O. Lambotte, P. Morlat, P. Reiss, P. Reiss, P. Reiss, P. Tookey, R. Lodwick, R. Paredes, R. Teira, R. Thiebaut, R. Zangerle, R. Zangerle, R.Teira, S. Ayayi, S. De Wit, S. Grabar, S. Matheron, S. Perez-Hoyos, T. Goetghebuer, V. Bouteloup, V. Le Moing, V. von Wyl, Y. Young   +113 more
core   +6 more sources

Lamivudine (3TC), a Nucleoside Reverse Transcriptase Inhibitor, Prevents the Neuropathological Alterations Present in Mutant Tau Transgenic Mice. [PDF]

Int J Mol Sci, 2023
Vallés-Saiz L, Ávila J, Hernández F.
europepmc   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A, Deming, Timothy, Elliott, Julie, Fulcher, Jennifer A, Ibarrondo, F Javier, Kickhoefer, Valerie A, Maynard, Heather D, Mrazek, Jan, Rome, Leonard H, Tamshen, Kyle, Wollenberg, Alexander L, Yang, Otto O   +11 more
core  

Patterns of transmitted HIV drug resistance in Europe vary by risk group [PDF]

, 2014
Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported ...
Abecasis, A.B. (Ana), Albert, J. (Jan), Balotta, C. (Claudia), Bergin, P., Beshkov, D. (Danail), Boucher, C.A.B. (Charles), Camacho, R.J. (Ricardo Jorge), Clotet, B. (Bonaventura), Frentz, D. (Dineke), Griskevicius, A. (Algirdas), Grossman, Z. (Zehava), Hamouda, O. (Osamah), Horban, A. (Andrzej), Jørgensen, L.B. (Louise), Kolupajeva, T. (Tatjana), Korn, K. (Klaus), Kostrikis, L.G. (Leondios), Kücherer, C. (Claudia), Linka, K.L.M. (Kirsi Liitsola Marek), Nielsen, C. (Claus), Otelea, D. (Dan), Paraskevis, D. (Dimitrios), Paredes, R. (Roger), Poljak, M. (Mario), Puchhammer-Stöckl, E. (Elisabeth), Schmit, J.-C. (Jean-Claude), Sonnerborg, A. (Anders), Stanekova, D. (Danica), Stanojevic, M. (Maja), Struck, D. (Daniel), Vandamme, A.M. (Anne Mieke), Vercauteren, J. (Jurgen), Vijver, D.A.M.C. (David) van de, Wensing, A.M.J. (Annemarie), Åsjö, B. (Birgitta)   +34 more
core   +1 more source